Blog

Regular posts covering guidance changes, inspection findings, data methodology, and Redica product updates.

Open filters
Search
Tags
Author
Aditi Singhai
Alison Sathe
Anders Vinther
Anne-Caroline Boillot
Barbara W. Unger
Barry Price
Jackie Torfin
Jerry Chapman
Jon Falker
Katie Terry
Khushboo Agrawal
Mark Agostino
Michael de la Torre
Rebecca Stauffer
Redica Systems
Roger Angarita
Sarah Boynton
Scott Sherrill
Tashil Sharma
Subscribe to our Newsletter
Regular posts covering guidance changes, inspection findings, data methodology, and Redica product updates.
Subscribe

On-Demand Webinar | The Insider’s Guide to FDA Audit Readiness

October 18, 2022
Redica Systems
No items found.

How “Inevitable” Data Integrity Issues Cause Havoc: Part I

October 14, 2022
Redica Systems
No items found.
Conference Spotlight

Navigating Drug Approvals and Post-Approval Changes in the Asia-Pacific Region

October 11, 2022
Jerry Chapman
101
APAC
Asia-Pacific
Drug Approval
Pharma

Why am I Being Inspected Again So Soon After a Pre-Approval Inspection?

October 6, 2022
Jerry Chapman
101
CDER
CVM
FDA
GMP
Conference Spotlight

How To Get Drug Products Approved In Asia-Pacific Markets

October 5, 2022
Jerry Chapman
101
APAC
Pharma

On-Demand Webinar | Top 10 Regulatory Surveillance Signals

October 4, 2022
Redica Systems
No items found.
Conference Spotlight

Who Decides if my FDA Inspection is Classified OAI?

September 29, 2022
Jerry Chapman
483
CFR
Code of Federal Regulations
compliance officer
FDA
Conference Spotlight

Getting Drugs Approved in Mexico, Argentina, Colombia, And Peru

September 27, 2022
Jerry Chapman
101
ANMAT
Argentina
COFEPRIS
Colombia

Good Quality, Poor Quality in the Pharmaceutical Industry

September 22, 2022
Anders Vinther
blame culture
contract manufacturing
guest article
Pharma
Quality
Conference Spotlight

How to Get New Drugs Approved in Brazil

September 21, 2022
Jerry Chapman
ICH
Latin America
Pharma

Where is My EIR?

September 20, 2022
Jerry Chapman
EIR
FDA
FDA inspection
Francis Godwin
NAI
Conference Spotlight

FDA on Compliance Issues in Pharma

September 16, 2022
Jerry Chapman
Donald Ashley
FDA
FDA inspection
Francis Godwin
GMP

Redica Responds: How Many GMP Inspections Have Resulted in a 483?

September 14, 2022
Redica Systems
483
FDA inspection
GMP
Pharma
Redica
Conference Spotlight

CMC Challenges and Opportunities in Latin America

September 13, 2022
Jerry Chapman
CMC
Drug Approval
Latin America
Pharma
Trends

PAIs and 483 Issuance Risk: The Trends Are Not What They Seem

September 8, 2022
Redica Systems
483
deviations
Enforcement Analytics
FDA
pre-approval inspections

Redica Responds: Do You Know Where Your Quality Unit Is?

September 7, 2022
Redica Systems
483
483 observations
quality unit

ALCOA Data-Integrity Principles: A Complete 2025 Guide

September 6, 2022
Redica Systems
483 observations
ALCOA
ALCOA-C,
consent decree
EMA

Redica Responds: Top Quality Systems Issues at Medical Device Sites

August 31, 2022
Redica Systems
Devices
FDA inspection
quality system
Redica Responds

Other Resources

Assessments

Insights on inspections, risk and compliance

Reports

Benchmark industry trends and best practices

Webinars

Hear from industry leaders and Redica experts.